Research and Practice in Thrombosis and Haemostasis

Article	Citations
PB0679 Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States	76
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro	55
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina	50
PO04 SARS-CoV-2 Vaccinations and Risk of Venous Thrombosis - Case Control Study	48
PO16 Hemorrhagic Complications in Patients with Hemophilia A	44
PB0796 Interferon Treatment Suppresses in vitro NETosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms	42
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec	40
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)	39
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells	39
PB0249 Some Coagulation Profiles (PT, APTT, TT, FIB), Red Cell, Total White Cell, Platelet Counts and Their Indices Activity Levels in Persons Exposed to Wood Smoke (Firewood) in Calabar, Nigeria	36
PB1060 Thrombin Generation and Fibrin Clot Structure in Nephrotic Patients with Primary Glomerular Disorders	35
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)	34
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing	33
PB0308 Anticoagulation Monitoring of UFH (Unfractioned Heparin) in a Pediatric Patient during Long Term ECMO (Extracorporeal Membrane Oxygenation)	33
PB1140 Laboratory Features and Genotype of a Family with Heritable Dysfibrinogenaemia (HD)	30
PB0358 Hereditary Bleeding Disorders Web-Based Registry of Patients with Inherited Platelet Disorders	27
PB1142 A Rapid Centrifugation 4000 g, 4 min Does not Impact Routine Coagulation Assays	27
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia	27
PB0403 A Common Variant in GRK5 Reveals a PAR1-Specific Regulation in Platelets	26
PB0412 Simulating the Impact of Thrombin on Platelet Function Requires Simultaneous Activation of Both PAR-1 and PAR-4	25
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis	23
PB0612 COVID-19: Predictive Value of Methemoglobinemia	23
PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center	22
OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study	22
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study	22

PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic	21
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA	21
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study	21
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma	20
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS	20
PB0926 Venous Thromboembolism and Risk of Depression in Patients with Hematological Cancer: A Population-Based Cohort Study	20
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database	20
OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Pan	19
OC 71.5 Reasons for Anticoagulation Failure and Provider Management	19
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study	19
OC 50.1 Levels of IgG4 Distinguish Immune Tolerance Induction Outcome in Patients with Inherited Hemophilia A: Results from the BrazIT Study	19
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients	19
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)	19
Navigating the inevitable: artificial intelligence and the future of scientific communication	18
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China	18
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis	18
Erratum to ‘A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.’ [Research and Practice in Thrombosis and Haemostasis Vo	18
Issue Information	18
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis	18
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study	18
How to use and report data on D‐dimer testing in the COVID‐19 era?	17
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality	17
Thrombo‐inflammatory biomarkers and D‐dimer in a biracial cohort study	17
Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists	17
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms	17
Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia	17
140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients	16
84 Rural Improvements in Venous Thrombosis Treatment in Oklahoma: The RIVETT-OK Initiative	16
128 Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting	16
Intraindividual variability of von Willebrand factor and the need for repeated testing	16
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach	16
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates	16
141 Heparin Management - The Ultimate Goldilocks Dilemma: A Quality Improvement Project	16
Exploration of biomarkers for inhibitor development in persons with hemophilia A	15
Thrombophilia and outcomes of venous thromboembolism in older patients	15
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation	15
Cryo‐EM structures of coagulation factors	15
Accumulating evidence for direct oral anticoagulants in liver disease	15
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	15
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany	14
Communication at diagnosis of venous thromboembolism: Lasting impact of verbal and nonverbal provider communication on patients	14
Rare inherited coagulation disorders: no longer orphan and neglected	14
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3	14
Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature	13
Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: A retrospective cohort study	13
Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound	13
OC 77.1 Development, Validation, and Implementation of a Decision Support Tool for the Screening of Mild Bleeding Disorders	13
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people	13
The diagnostic utility of genetic testing in inherited thrombocytopenia: regional multicenter tertiary experience	13
The use of qualitative methods in venous thromboembolism research	13

Advanced practice provider–led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization	13
Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations	12
Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer	12
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center	12
D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap	12
Lower early mortality and risk prediction improvement of obesity after acute pulmonary embolism: results from a multicenter cohort analysis with external validation	12
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study	12
Changes in body mass index following venous thromboembolism in children: a prospective cohort study	12
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism	12
Probing rare von Willebrand disease–causing mutations in the D4 and C-domains of von Willebrand factor	12
Editorial Board	12
Relevance of anti–platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic	12
OC 11.1 Development and Validation of a Clinical Prediction Model for the Diagnostic Management of Acute Pulmonary Embolism: An Individual Participant Data Meta-Analysis	11
Extracellular vesicle tissue factor and tissue factor pathway inhibitor are independent discriminators of sepsis-induced coagulopathy	11
PB1133 DaXa, a Non-Calibrated Anti-FXa Assay that can be Used to Quantify DOAC Concentration in Acute Medical Emergencies	11
PB0380 Corrections of Bernard Soulier Syndrome Megakaryocyte Phenotypes by Small Molecules and Interleukin-1α	11
PB1072 A Novel Factor VIII Specific APC Resistance Assay	11
OC 03.4 A Common, Racially Diverse Protease Activated Receptor 4 Functional Variant Impacts Ischemic Stroke Outcomes: Evidence for a Pharmacogenetic Effect	11
Managing surgical relapse risk in acquired thrombotic thrombocytopenic purpura: a systematic review	11
PB1152 Reporting of DOAC Concentration as FXa Inhibitory Units - Potential Solution for Smaller Laboratories?	11
PB1176 Analytical Performances Evaluation of the sthemO VWF:Ag Assay on the sthemO 301 Analyzer	11
PB1146 Comparison of Three Warfarin Monitoring Tests (PT, P&P and Fiix test) in Anticoagulated and Non-Anticoagulated Lupus Anticoagulant Positive Plasma Samples	11
PB0979 Significantly Increased CVC Replacement in Patients with Both Symptomatic and Incidental Venous Thrombotic Events in Pediatric Cancer Patients: A Population-Based Study	11
PB0311 Anticoagulation in a Hypercoagulable Infant with End-Stage Renal Disease on Renal Replacement Therapies	11
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study	11
Bedside exclusion of pulmonary embolism in children without radiation (BEEPER): a national study of the Pediatric Emergency Care Applied Research Network—Study protocol	11
PB1156 Clinical Performance Evaluation of the New Stago System for Fibrinogen and Thrombin Time Determination: sthemO Fib and sthemO Thrombin on sthemO 301 Analyzer	11
PB1013 Evaluation of the Diagnostic Performance of Three D-Dimer Assays in Patients with Suspected Deep Vein Thrombosis	11
HTRS2023.P2.3 F8 variants in women and girls evaluated for hemophilia A	10
PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand	10
PB0695 Comparison of Platelet Quality and Hemostatic Function Across Apheresis Collection Platforms	10
PB0723 Protease-Activated Receptor 4 Differentially Modulates TLR3- Dependent Responses In Vitro and In Vivo	10
PB0150 Fibrin Clot Formation is a Reliable Biological Marker to Evaluate FVIII Replacement Therapy in Hemophilia A Patients	10
PB1210 Incorporation of a2-Plasmin Inhibitor into Plasma Clots of Patients with Venous Thrombosis	10
PB0421 Phosphoproteomics and Systems Analysis Reveal Protein Kinase C Theta (PKCfɵ) Signaling Events Associated with the Generation of Procoagulant Platelets	10
PB1427 Reduced ADAMTS13 Activity in Staphylococcus Aureus Bacteremia is Associated with Neutrophil-Mediated Citrullination	10
PB0117 COVID-Associated Thrombosis: New Insights	10
PB0706 Mechanism by which Coagulation Factor XI Regulates Endothelial Cell Permeability and Barrier Function In Vitro and In Vivo	10
PB1519 Analysis of Aggregation Patterns Changes in Pregnant Women with Severe Preeclampsia	10
PO26 Pulmonary Embolism in a Case with Thrombotic Thrombocytopenic Purpura after Plasmapheresis	10
PB1383 RUNX1-Mutated Familial Platelet Disorder (RUNX1-FPD) with Associated Acute Myeloid Leukaemia - A Case/Family Series	10
PB0448 Fibrin Clot Properties Identify Patients that Benefit from Catheter- Directed Thrombolysis: A Post Hoc Analysis of the CAVA Trial	10
HTRS2023.P2.16 Prevalence of iron deficiency in patients with inherited bleeding disorders	10
PB1193 Acute Myocardial Infarction Thrombi Show Fibrin Film that Increases with Ischaemia Duration	10
PB1433 Opposing Effects of Canonical and Non-Canonical PAR-1 Activation in Experimental Diet-Induced Obesity and Fatty Liver Disease	10
PB1466 Early Mortality in Pulmonary Embolism - A Systematic Review and Analysis	10
OC 22.1 Proteome and Phosphoproteome Analyses of SARS-CoV-2 Infected Humanized ACE2 Mice Platelets Revealed Reprogramming of Platelets from Early Hyperreactive to Late Antiviral Phenotypes	10
PB1377 Living with Glanzmann's Thrombasthenia: An Interim Report from the Glanzmann's 360 International Patient Survey	10
PB0437 Concordance of Phosphatidylserine/Prothrombin and APhL Antibodies Associated with Antiphospholipid Syndrome-Associated Pregnancy Morbidity	10
Comparison of different algorithms for lupus anticoagulant detection: a single-center experience	9
OC 54.2 Comparison of Direct Oral Anticoagulants versus Low Molecular Weight Heparin in Primary and Metastatic Brain Cancers: A Meta-Analysis and Systematic Review	9
Galectin-3-binding protein and future venous thromboembolism	9
Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients	9
Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)	9
Incidence rate of venous thrombosis in women switching combined oral contraceptives: a cohort study	9
Management of congenital dysfibrinogenemia in pregnancy: A challenging patient case	9
Patients with metabolic dysfunction–associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs	9
Issue Information	9
Factor V variants in bleeding and thrombosis	9
Arthropathy on X-rays in 363 persons with hemophilia: long-term development, and impact of birth cohort and inhibitor status	9
PB0005 The Interest of the Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in the Prediction of Thrombus in Myocardial Infarction	9
OC 70.2 The First Insight into the Spatial Structure of Human Kininogen by Cryogenic Electron Microscopy and Computational Methods	9
Regulation of megakaryo/thrombopoiesis by endosomal toll-like receptor 7 and 8 activation of CD34+ cells in a viral infection model	9
132 Antithrombotic Prescribing Practices in Patients with Atrial Fibrillation Presenting with Acute Ischemic Stroke while on Oral Anticoagulation	9
Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function	9
A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen−deuterium exchange plus mass spectrometry	9
Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized r	9
Exploring heterogeneity in reported venous thromboembolism risk in COVID-19 and comparison to other viral pneumonias: a systematic review and meta-regression	9
Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations	9
OC 72.5 Prediction of Venous Thromboembolism in Diverse Ancestry Populations Using Machine Learning and Electronic Health Records	9
OC 75.3 Phenotype and Genotype Characterization of Patients with Congenital Fibrinogen Deficiencies: A Retrospective Analysis of the PRO-RBDD Database	9
OC 60.1 Delineating VonWillebrand Factor Genetic Variants in Patients with a Von Willebrand Disease Diagnosis	9
Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay	9
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States	9
Response to: “Are women equal? Considering impact of therapeutic abortion bans on science”	9
Machine learning analysis of bleeding status in venous thromboembolism patients	9
Thrombin generation and implications for hemophilia therapies: A narrative review	9
Tissue factor-heparanase complex: intracellular nonhemostatic effects	9
PB0945 Effect of Drug Interactions with Apixaban on Clinical Outcomes in Cancer Patients with Venous Thromboembolism	8
LB 01.4 Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis	8

HTRS2023.P4.20 Systematic review of global hemostasis assays in myeloproliferative neoplasms: promising tools for biomarkers for hypercoagulability	8
OC 35.3 Correlation between ETP-Based APC Resistance and the Relative Risk of Venous Thromboembolism in Women Using Combined Oral Contraceptives	8
OC 42.2 Incidence and Risk Factors of Major Adverse Cardiovascular Events in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura during Remission	8
OC 50.2 Low Dose FVIII Injections as a Potential Treatment to Prevent Inhibitor Development in Hemophilia a - an in Vivo Study	8
PB1161 Evaluation of Three Prothrombin Time Reagents and their Sensitivity to Extrinsic Pathway Factor Deficiencies (FII, FV and FVII)	8
PB0865 Endothelial Extracellular Vesicles Regulate In Situ Pulmonary Thrombosis in Sickle Cell Disease	8
PB0910 Evaluation of the Clot Formation Tranfusing Fresh, Cold and Frozen Platelets. Advantages for the Military Environment	8
PB0141 Characterizing the Transcriptomic Profile of Acquired Hemophilia Using RNA-Seq	8
PB1027 Delayed Diagnosis and Treatment of Deep Vein Thrombosis-an Underrecognized Factor for Its Related Complications?	8
OC 38.3 Effects of Apixaban Versus No Anticoagulation on Biomarkers of Thrombin Generation in Pediatric Acute Lymphoblastic Leukemia (ALL): A Biomarker Sub-Study of PREVAPIX-ALL, a Randomized Controll	8
PB0908 Therapeutic Efficacy of Platelet-Rich Plasma in Chronic Compression of the Dorsal Root Ganglion in Rat	8
PB1527 Sticky Platelet Syndrome and Pregnancy Complications - 18 Years' Experience in National Center of Hemostasis and Thrombosis in Slovak Republic	8
PB1153 Shortening of APTT when Heparin Neutralising Calcium Solution Replaces Calcium Alone is Highly Specific for the Presence of Heparin	8
HTRS2023.O8B.3 Elucidating the molecular mechanism of excessive phosphatidylserine exposure in sickle red cells	8
PB0153 Evaluation of Cell Type-Specificity of Native Enhancer Elements from the F8 Locus	8
OC 27.2 Mechanistic Studies of Runt-Related Transcription Factor-1 (RUNX1)-Deficient Megakaryopoiesis and its Correction by RepSox (RS), a TGFβ-Receptor-1 Inhibitor	8
PB0994 Intronic Exploration of PROC in Patients with Unexplained Protein C Deficiencies	8
OC 10.3 Platelets Mediate Intracranial Aneurysm Formation and Rupture in Mice	8
OC 60.5 Response to Desmopressin in Type 2N Von Willebrand’s Disease: A Genotype-Phenotype Analysis on a Cohort of 121 Patients	8
PB0408 Regulation of Collagen Binding Integrins by Alpha 7 and C Helix	8
PB0452 Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro- Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism	8
OC 63.3 Combined Effect of High Factor VIII Levels and High Mean Platelet Volume on the Risk of Future Venous Thromboembolism	8
How I respond to peer reviewer comments	7
Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing	7
PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status	7
PB0545 The Effect of a History of Preeclampsia on Hemostatic Balance in the Non-Pregnant State	7
PB1520 Deep Learning Extracts Embedded Signatures Associated with Pregnancy and Preeclampsia from Circulating Vesicle Profiles	7
PB0633 Understanding the Requirement for Additional Factor VIII Infusion Associated with Novel Haemophilia A Treatments: An Expert Elicitation Exercise	7
PB1345 Health-Related Quality of Life Assessed by the SF-36 Health Survey in the Vienna ITP Biobank	7
PB1062 Exogenous Warfarin Intoxication Associated with Munchaüsen Syndrome	7
PB0518 Novel Insights into Antifibrinolytic and Prothrombotic Functions of Lipoprotein(a)	7
PO34 The Risk of Vein Thromboembolism and Prevention in the Critically Illness Facilitated with an Electronic Decision Support System	7
PB0708 The Tissue Factor/Thrombin Axis Limits Spontaneous Lymphatic Metastasis in Mice	7
Recombinant factor VIIa: new insights into the mechanism of action through product innovation	7
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib	7
The Evolution of Hemophilia Therapeutics: An Illustrated Review	7
Joint effect of ischemic stroke and obesity on the risk of venous thromboembolism: the Tromsø Study	7
PB0127 D-Dimer: Advantage Lost in the Post COVID Era?!	7
PB0659 Patients with Hemophilia A have Increased Levels of Circulating Activated Protein C: Potential Contribution to their Hemostatic Status	7
PB1517 Effect of Uteroplacental Manipulation on Hemostatic Markers during Cesarean Delivery and Hysterectomy for Placenta Accreta Spectrum	7
PB1388 Sticky Platelet Syndrome: Clinical Experience from a Tertiary Center	7
PB0319 Overexpression of ANKRD26 Results in Thrombocytopenia That May Exacerbate Clinical Phenotypes of Thrombotic Thrombocytopenic Purpura	7
PB1059 Single Amino Acid Substitutions of an Antibody Specific for a Non-Active Site of Activated Protein C (APC) Yielded an Antibody Library Capable of Modulating and Uncoupling APC Pleiotropic Funct	7
PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Stud	7
PB0699 Idarucizumab for Dabigatran Reversal: A Systematic Review and Meta-Analysis of Indications and Outcomes	7
PB0911 Platelet Reactivity in Patients with Atrial Fibrillation and Coronary Artery Disease under IIa Antagonists and Xa Antagonists	7
Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement	7
Underrepresentation and undertreatment of women in hematology: An unsolved issue	7
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)	7
Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A	7
PB1424 PCF11 is a Central Hub in the Regulation of Inflammation in an Animal Model of Septicemia	7
PB0047 COVID-19 Infection-Associated Platelet and Neutrophil Activation is Blunted by Previous Anti-SARS-CoV-2 Vaccination	7
PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study	7
Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study	7
PB0595 The Profile of Contact Activation System Proteins in Human Abdominal Aortic Aneurysm Plasma-and Tissue Samples	7
PB0233 Von Willebrand Disease in the East Mediterranean Region: Current Situation and Gaps	7
PO08 Factor XIII Deficiency as Underlying Cause of Unexplained Intracranial Hemorrhage	7
PB0812 The Importance of the Amino-Acid Residue at Position 2561 in the C4-Domain of von Willebrand Factor	7
PB0315 Characterizing Protease-Resistant ADAMTS13 Mutants	7
PB0707 Neutrophil Extracellular Traps Promote Cancer-Associated Inflammation and Myocardial Stress	7
PB1461 Peri-Operative Venous Thromboembolism (VTE) Risk for Below Knee Amputations	7
OC 16.4 Thrombin Generation is Associated with Stroke in a General Adult Population: Prospective Findings from the Moli-Sani Study	6
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies	6
LB 01.5 Effect of the P-selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial	6
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study	6
PB0041 Prevalence of Vascular Risk Factors and I/D Angiotensin-Converting Enzyme Gene (ACE) Polymorphism in Costa Rican Elderly Patients with Cognitive Impariment	6
HTRS2023.O8A.3 Bringing PERT to pediatrics: implementing and examining outcomes of the first pediatric Pulmonary Embolism Response Team (PERT)	6
PB1136 Improving Genetic Testing for Antithrombin Deficiency by Optimizing ACMG/AMP Variant Curation Guidelines for the SERPINC1 Gene	6
PB1325 A Novel Recombinant Factor VII D60A May Potentially Reduce the Risk of Thrombotic Complications	6
PB0810 Investigating ADAMTS13 Cleavage of von Willebrand Factor under Flow	6
PB0763 Sudden Bilateral Deafness Revealing Anti Phospholipid Syndrome	6
Editorial Board	6
OC 25.3 A Multicentre Cohort Study Evaluating Pregnancy Loss in Patients with Von Willebrand Disease and Unspecified Bleeding Disorders	6
HTRS2023.P4.10 Endothelial ERp46 supports tissue factor activity	6
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes	6
HTRS2023.P4.1 Effect of heparin induced thrombocytopenia on outcomes of pulmonary embolism: a nationwide inpatient sample study	6
Tranexamic acid for management of heavy vaginal bleeding: barriers to access and myths surrounding its use	6
Re: Hormonal therapies and venous thrombosis: The estrogen matters! Morimont et al.	6
OC 13.3 O-Glycan and Sialic Acid Residues Differentially Regulate Von Willebrand Factor Trafficking, Storage and Secretion	6
PB0656 Impact of Moderate to Vigorous-Intensity Physical Activities on Pharmacokinetic-Guided Extended Half-Life FVIII Concentrates Prophylaxis Severe Hemophilia A Patients	6
PB0820 In Silico Evidence of the Conformational Transitions Associated with the p.R854Q Mutation in the D'D3 Domain of von Willebrand Factor, Responsible for Its Weakened FVIII Interaction	6
PB0798 Role of Platelets in Maintain Lung Hemostasis during dsRNA-Induced Acute Respiratory Distress Syndrome (ARDS) in Mice	6
PB0892 C-3399 Inhibitor of PDI Isoforms with an Attractive Profile of Antiplatelet Action	6
OC 14.3 A Novel Strategy to Combat the Procoagulant Phenotype in Immune Thrombotic Thrombocytopenia using 12-LoX Inhibition	6
HTRS2023.P1.6 Characterization and expression of atypical type 2B variants in the Zimmerman Program	6
Title page	6
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis	6
Thromboprophylaxis in multiple myeloma	6
PB0054 Impact of Variations in Sex Hormone Levels on the Hypercoagulability and Severity of COVID-19 in Women and Men According to Age. The ROADMAP-COVID-19 Study	6
PB0124 Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet Activating Factor and its Precursors: A Combined Metabolomic and Lipidomic Approa	6
PB0574 Severe Bleeding in an Acquired Factor XIII Deficiency in an Otherwise Healthy Patient	6
PO42 Thrombocytopenia Induced by Anticancer Agents (TIANA) in Lung Cancer	6
PB0776 Characterization of the Effects of Hydroxyurea and Crizanlizumab on Plasma Immunothrombosis Biomarkers in Patients with Sickle Cell Disease	6
PB0628 The World Federation of Hemophilia Living Guidelines Model	6
OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates	6